Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended March 31, 2025
Business Overview: InMed is a clinical-stage pharmaceutical company developing proprietary small molecule drug candidates targeting diseases with high unmet medical needs (Alzheimer's, dry AMD, Epidermolysis Bullosa). It operates two segments: InMed Pharma (R&D) and BayMedica Commercial (manufacturing and sale of bulk rare cannabinoids for the health and wellness sector).
Going Concern: The Company has concluded there is substantial doubt about its ability to continue as a going concern within one year due to recurring losses and negative cash flows. Cash on hand is projected to fund operations only into the third quarter of calendar 2025.
Key Financial Metrics
| Metric (USD) | 9 Months Ended Mar 31, 2025 | 9 Months Ended Mar 31, 2024 | 3 Months Ended Mar 31, 2025 |
|---|---|---|---|
| Revenue | $3,637,923 | $3,314,663 | $1,261,578 |
| Net Loss | $(6,373,822) | $(5,737,879) | $(2,120,930) |
| Net Loss Per Share (Basic/Diluted) | $(7.93) | $(16.48) | $(1.94) |
| Cash & Cash Equivalents | $4,679,826 | $7,600,598 (End of Period) | $4,679,826 |
| Short-term Investments | $40,582 | $43,064 | $40,582 |
| Total Current Assets | $6,410,063 | $8,689,585 | $6,410,063 |
| Total Current Liabilities | $1,838,962 | $1,971,808 | $1,838,962 |
| Accumulated Deficit | $(115,449,581) | $(107,138,088) | $(115,449,581) |
| Operating Cash Flow | $(5,988,445) | $(5,956,668) | N/A |
| Financing Cash Flow | $4,096,661 | $4,654,042 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10% year-over-year for the nine months ended March 31, 2025, driven by the BayMedica Commercial segment. Sales rose from $3.31M to $3.64M.
- Profitability: Despite revenue growth, the Net Loss increased by approximately 11% (from $5.74M to $6.37M) due to higher operating expenses and a significant one-time finance expense.
- Operating Expenses: Total operating expenses increased by 7% to $7.26M. Research and Development (R&D) expenses rose 7% to $2.74M, primarily due to increased external contractor costs for INM-901 and INM-089 programs.
- Unusual Items: The Company recorded a finance expense of $351,549 related to the Standby Equity Purchase Agreement (SEPA) commitment fees, which were expensed rather than capitalized due to accounting standards (ASC 815-40-25).
- Capital Structure: The Company effected a 20-for-1 reverse stock split on November 14, 2024. All share and per-share data have been adjusted retrospectively.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash and short-term investments ($4.7M) to fund operations only into the third quarter of 2025. The Company is actively seeking additional funding through equity financings, debt, or strategic transactions.
- Financing Activities:
- SEPA: Entered a $10M Standby Equity Purchase Agreement in December 2024. Issued 413,336 shares for ~$2.5M gross proceeds during the period. Shareholder approval is required to issue shares exceeding 19.99% of outstanding shares.
- ATM Program: The S-3 registration statement for the At-the-Market offering expired on February 10, 2025. The Company may file a new registration to resume sales.
- Operational Milestones:
- INM-901 (Alzheimer's): Positive preclinical results announced in January 2025 showing reduced neuroinflammation markers.
- INM-089 (Dry AMD): Selected an intravitreal formulation for preclinical studies in February 2025.
- Risks and Contingencies:
- Legal Proceedings: BayMedica is involved in a dispute regarding a Patent License Agreement. The Licensor has initiated arbitration proceedings (April 2025). The Company cannot estimate potential losses at this time.
- Customer Concentration: Revenue is highly concentrated; two customers accounted for 56% of revenue in the three months ended March 31, 2025.
- Trade Policy: Potential impact of new U.S. tariffs and trade restrictions announced in early 2025 remains uncertain.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern warning and the projection of funds lasting only into Q3 2025.
- SEPA Terms: Review the specific conditions for the Standby Equity Purchase Agreement, particularly the 19.99% issuance cap and the requirement for shareholder approval to exceed it.
- Arbitration Outcome: Monitor the status of the Patent License Agreement arbitration initiated by BayMedica's licensor, as this could result in significant liabilities or loss of exclusivity.
- ATM Status: Confirm if a new S-3 registration statement has been filed to reactivate the At-the-Market offering program.
- Customer Dependency: Assess the risk associated with the high concentration of revenue from two primary customers in the BayMedica segment.